avirin for patients with genotypes 2 and 3 hepatitis C, two relatively uncommon forms of the infection.Panellists also backed sofosbuvir's use in combination with ribavirin and pegylated interferon alfa as a treatment for the more prevalent genotype 1 form of hepatitis C, which accounts for around 70 per cent of all cases in the US, as well as patients with genotype 4.Sofosbuvir is the first compo